The First Disclosures sessions at the 2023 ACS Fall Meeting in San Francisco, organized by Nikki Goodwin, presented a variety of new orally available small molecules. The standing room-only sessions were so highly attended that many attendees were unfortunately kicked out due to the fire code. In case you missed any of these exciting molecules, from Scorpion’s mutant-selective PI3Kα inhibitor to Nurix’s CNS-penetrant BTK degrader, here we share the structures and targets of all the novel molecules disclosed at the session.
The newly disclosed small molecule therapeutics included:
- TNG-462: An oral MTA-cooperative PRMT5 inhibitor (Tango Therapeutics)
- STC15: A first-in-class and first-in-clinic oral METTL3 inhibitor (Storm Therapeutics)
- STX-478: An oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor (Scorpion Therapeutics)
- JNT-517: An oral allosteric SLC6A19 inhibitor (Jnana Therapeutics)
- CHK-336: A first-in-class oral, liver-targeted LDHA inhibitor (Chinook Therapeutics)
- GDC-6599: A first-in-class oral TRPA1 inhibitor (Genentech)
- KIN-3248: An oral covalent pan-FGFR inhibitor (Kinnate Biopharma)
- NX-5948: An oral CNS-penetrant BTK targeted degrader (Nurix Therapeutics)
- KT-474: An oral selective IRAK4 degrader (Kymera, Sanofi)
- RPT193: An oral CCR4 antagonist (RAPT Therapeutics)
- EDI048: A first-in-class oral soft-drug Cp PI(4)K inhibitor (Novartis)
- PF-07817883: A metabolically-stable SARS-CoV-2 Mpro inhibitor (Pfizer)
Our team will be covering each molecule in more depth in the coming days. Stay tuned!